Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Late-stage results from the probe development effort to identify antagonists of OPRK1: luminescence-based cell-based dose response OPRM1 counterscreen, Set 2
Assay data:2 Active, 11 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by DepositorRelated BioAssays by Same ProjectRelated BioAssays by Target
Late-stage results from the probe development effort to identify antagonists of OPRK1: fluorescence-based cell-based dose response OPRD1 counterscreen
Assay data:5 Active, 14 Tested
Summary of the probe development efforts to identify antagonists of the kappa 1 (OPRK1) opioid receptor
SummaryPubMed CitationRelated BioAssays by DepositorRelated BioAssays by Same ProjectRelated BioAssays by Target
Late-stage results from the probe development effort to identify antagonists of OPRK1: radiometric-based biochemical hERG counterscreen assay
Assay data:1 Tested
Late-stage results from the probe development effort to identify antagonists of OPRK1: LCMS-based biochemical cytochrome P450 inhibition assay
Assay data:1 Active, 1 Tested
Late-stage fluorescence-based cell-based dose response assay for antagonists of kappa opioid receptor 1 (OPRK1)
Assay data:7 Active, 1 Activity ≤ 1 µM, 11 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by DepositorRelated BioAssays by Same ProjectRelated BioAssays by Target
Late-stage results from the probe development effort to identify antagonists of OPRK1: LCMS-based pharmacokinetic plasma protein binding assay
SummaryCompounds, ActivePubMed CitationRelated BioAssays by DepositorRelated BioAssays by Same Project
Late-stage counterscreen for antagonists of kappa opioid receptor 1 (OPRK1): fluorescence-based cell-based dose response assay to identify antagonists of Sphingosine 1-Phosphate Receptor 1 (S1P1)
Assay data:11 Tested
Late-stage results from the probe development effort to identify antagonists of OPRK1: fluorescence-based cell-based dose response OPRD1 counterscreen, Set 2
Assay data:1 Active, 11 Tested
Late-stage results from the probe development effort to identify antagonists of OPRK1: LCMS-based parallel artificial membrane permeability (PAMPA) assay
Fluorescence-based cell-based confirmation assay for antagonists of kappa opioid receptor 1 (OPRK1)
Assay data:22 Active, 67 Tested
Late-stage results from the probe development effort to identify antagonists of OPRK1: CEREP radiometric-based biochemical counterscreen panel assay
Late-stage results from the probe development effort to identify antagonists of OPRK1: fluorescence-based cell-based dose response assay, Set 2.
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
Late-stage results from the probe development effort to identify antagonists of OPRK1: LCMS-based in vivo plasma and brain levels
Late-stage results from the probe development effort to identify antagonists of OPRK1: luminescence-based cell-based dose response counterscreen assay to determine cytotoxicity of test compounds
SummaryPubMed CitationRelated BioAssays by DepositorRelated BioAssays by Same Project
Counterscreen for antagonists of kappa opioid receptor 1 (OPRK1): fluorescence-based cell-based assay to identify antagonists of Sphingosine 1-Phosphate Receptor 1 (S1P1)
Assay data:29 Active, 67 Tested
Late-stage results from the probe development effort to identify antagonists of OPRK1: LCMS-based biochemical hepatic microsome stability assay
Late-stage results from the probe development effort to identify antagonists of OPRK1: In vivo tail flick assay
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on